Home Featured Page 227

Featured

Latest

Dee Dee Goldpaugh – Embracing Pleasure

Q3’25 Psychedelic Drug Development Pipeline: Bullseye Charts

‘No Prejudice, No Hype’: Florence Butlen-Ducuing on Europe’s Psychedelic Renaissance

August 2025 Psychedelic Patent Update

Unpacking FDA’s MDMA Rejection Letter and the Road Ahead for Lykos

Mindset Pharma Announces Publication of Three PCT Patent Applications for Its...

atai Life Sciences Reports Second Quarter 2021 Financial Results and Business...

Beckley Psytech completes oversubscribed $80m (£58m) fundraise to develop portfolio of...

Why Does The Psychedelic Scene Ignore PCP? [Part 1]

PT257 – Robin Divine – Black People Trip

PTSF71 – Sexual Ethics in Psychedelics and Mistrust of Big Pharma

Modernization of Sacred Plant Medicine Traditions: At What Cost?

PT256 – Matthew D. Segall, Ph.D. – Consciousness, Capitalism, and Philosophy

PTSF70 – Depth Psychology, The Reach of the DEA, and Progress...

Psychedelics, Religion, and the DEA’s Quest for Soul

1...226227228...296 Page 227 of 296

Dee Dee Goldpaugh – Embracing Pleasure

Q3’25 Psychedelic Drug Development Pipeline: Bullseye Charts

‘No Prejudice, No Hype’: Florence Butlen-Ducuing on Europe’s Psychedelic Renaissance

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

ABOUT US

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.

Featured

Dee Dee Goldpaugh – Embracing Pleasure

Q3’25 Psychedelic Drug Development Pipeline: Bullseye Charts

‘No Prejudice, No Hype’: Florence Butlen-Ducuing on Europe’s Psychedelic Renaissance

August 2025 Psychedelic Patent Update

Unpacking FDA’s MDMA Rejection Letter and the Road Ahead for Lykos

Mindset Pharma Announces Publication of Three PCT Patent Applications for Its...

atai Life Sciences Reports Second Quarter 2021 Financial Results and Business...

Beckley Psytech completes oversubscribed $80m (£58m) fundraise to develop portfolio of...

Why Does The Psychedelic Scene Ignore PCP? [Part 1]

PT257 – Robin Divine – Black People Trip

PTSF71 – Sexual Ethics in Psychedelics and Mistrust of Big Pharma

Modernization of Sacred Plant Medicine Traditions: At What Cost?

PT256 – Matthew D. Segall, Ph.D. – Consciousness, Capitalism, and Philosophy

PTSF70 – Depth Psychology, The Reach of the DEA, and Progress...

Psychedelics, Religion, and the DEA’s Quest for Soul

EDITOR PICKS

Dee Dee Goldpaugh – Embracing Pleasure

Q3’25 Psychedelic Drug Development Pipeline: Bullseye Charts

‘No Prejudice, No Hype’: Florence Butlen-Ducuing on Europe’s Psychedelic Renaissance

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

POPULAR CATEGORY